Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DBV Technologies Plans Strategy For Peanut Allergy Debut In U.S.

This article was originally published in The Pink Sheet Daily

Executive Summary

The French biotech will set out its stall first in the U.S., where peanut allergy is a major concern, and plans to tackle the life-threatening condition with its transdermal patch without relying on local partners.

You may also be interested in...



Aimmune Gets $145m From Nestlé To Advance Food Allergy Immunotherapies

With the sizeable investment, Nestlé Health Sciences also gets a three-month right of first negotiation for licensing or partnering to develop any Aimmune candidates, including Phase III AR101 for peanut allergy.

Peanut Allergy Targeted By DBV Technologies As It Raises $55 Million In Second Euro Biotech IPO This Year

France's DBV Technologies lists on NYSE Euronext in Paris and targets peanut and other food allergies for the first clinical studies of its epicutaneous patches as allergy desensitization therapies.

Takeda’s Alunbrig To Battle Entrenched EU Competitors In First-Line ALK-Positive NSCLC

EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS078594

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel